title: Issues in blood pressure control and the potential role of single-pill combination therapies.
abstract: Hypertension (HTN) is a major risk factor for cardiovascular mortality, yet only a small proportion of hypertensive individuals receive appropriate therapy and achieve target blood pressure (BP) values. Factors influencing the success of antihypertensive therapy include physicians' acceptance of guideline BP targets, the efficacy and tolerability of the drug regimen, and patient compliance and persistence with therapy. It is now well recognised that most hypertensive patients require at least two antihypertensive agents to achieve their target BP. However, complicated treatment regimens are a major contributory factor to poor patient compliance. The use of combination therapy for HTN offers a number of advantages over the use of monotherapy, including improved efficacy, as drug combinations with a synergistic mechanism of action can be used. This additive effect means that lower doses of the individual components can be used, which may translate into a decreased likelihood of adverse events. The use of single-pill combination therapy, in which two or more agents are combined in a single dosage form, offers all the benefits of free combination therapy (improved efficacy and tolerability over monotherapy) together with the added benefit of improved patient compliance because of the simplified treatment regimen. The use of single-pill combination therapy may also be associated with cost savings compared with the use of free combinations for reasons of cheaper drug costs, fewer physician visits and fewer hospitalisations for uncontrolled HTN and cardiovascular events. Thus, the use of single-pill combination therapy for HTN should help improve BP goal attainment through improved patient compliance, leading to reduced costs for cardiovascular-related care.
authors.affiliation: Division of Nephrology and Hypertension Consultation, CHUV, Lausanne, Switzerland. michel.burnier@chuv.ch
authors.forename: M
authors.initials: M
authors.lastname: Burnier
authors.forename: R E
authors.initials: RE
authors.lastname: Brown
authors.forename: S H
authors.initials: SH
authors.lastname: Ong
authors.forename: A
authors.initials: A
authors.lastname: Keskinaslan
authors.forename: Z M
authors.initials: ZM
authors.lastname: Khan
mesh_terms: D000959:Antihypertensive Agents / Q000191:economics / Q000627:therapeutic use*; D004338:Drug Combinations; D016527:Drug Costs; D004359:Drug Therapy, Combination / Q000379:methods; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics; D055118:Medication Adherence; D012307:Risk Factors; D013607:Tablets; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D004338:Drug Combinations; D013607:Tablets